changing the surface
of biotechnology
Kode Technology (FSL constructs) adds new functions to virtually any surface, living or inert, without harming living cells.
Biosurface engineering has never been easier.
Founded in New Zealand to develop, commercialise and license Kode Technology
Designing, making and selling FSL constructs
Research probes, including FSL constructs
Distribution through GlycoNZ and Merck MilliporeSigma
Kode Technology: biosurface engineering
Cells, bacteria and viruses recognise each other through shapes on their surfaces. Kode Biotech builds those shapes, and other functions, onto a lipid tail that sticks like paint to living and non-living surfaces, changing how they interact.
more on FSL constructsRead the transcript
Imagine a paint that uses shapes to prevent and cure illness. It's now possible.
Your body is filled with 37 trillion cells, 40 trillion bacteria, and often lots of viruses. They all look different and do different things, and can interact with each other through connecting shapes on each other's surfaces. Sometimes interactions can be good, like sperm finding an egg, or bad, like a virus causing the flu.
Imagine if we could change these interactions. Well, now we can, with Kode paint. Remember those shapes that the cell and the virus used to interact? We can copy them. And then we can attach a special tail on them that can stick, like paint, to a surface. There are lots of different paints we can make from shapes on cells, bacteria and viruses. All of this means scientists can do faster, better, smarter research to help change the future of medicine.
So what could Kode mean for you? We can help your medicine find the right place. Or stop you getting infections after surgery. Or make your bandage heal you faster. Or train a virus to find and kill your cancer. Or even teach your body to do it itself.
Painting the future. Kode Biotech and AUT.
Kode Technology is established: FSL constructs have been designed, made and sold for more than 20 years, and are used in research laboratories and blood-bank quality-control products worldwide. The medical uses at the end of this video are investigational research directions: none is approved by a medicines regulator. Investigational disclaimer
Kode Technology for scientists: explore the science
The Kode Technology Illustrated Technical Manual brings all known Kode Technology data together in one illustrated reference, free to download. Stephen Henry's DSc thesis, the peer-reviewed papers and the full bibliography go further.
University of Auckland National Library of NZKode Immunoeducers: cancer immunotherapy
An adjuvant-like initiator of an in situ autologous cancer vaccine. The KIE supplies the immune-initiating signal; the patient's tumour supplies the tumour antigens.
Human oncology
Veterinary oncology
Human oncology
K5K and Kv9 are Gen 3 KIE molecules, identical by structure. All KIE programmes are investigational.
more on Kode ImmunoeducersKode Group: one body of science
Kode Biotech is the holder and parent of companies that license Kode Technology for different sectors and uses. The group also includes GlycoNZ, which supplies a broad range of glycoconjugate research probes, including FSL constructs.
more on the Kode GroupOur partners: working together
Kode Biotech works with distributors, suppliers and charitable partners to take Kode Technology further.
Equitable Oncology
Independent New Zealand charity helping more people access cancer treatment. K5K is the first programme selected to progress through its model.
Merck MilliporeSigma
Global distributor of Kode FSL constructs and other research glycoconjugates.
Synpel Chemical
A Czech Republic chemical manufacturer that makes Kode FSL and GlycoNZ products.
Other partners
Research, manufacturing, and sales and distribution partners.
Kode Biotech timeline: three decades
From a New Zealand start-up in 1996 to a group of companies advancing Kode Technology for research, diagnostics and cancer immunotherapy, and supplying glycan research probes worldwide.
EOL partnership
latest news
Equitable Oncology launches
Equitable Oncology, an independently governed New Zealand charity and Kode Biotech's partner, launches. K5K is the first programme selected to progress through the Equitable Oncology Model.
equitableoncology.com → 2025Stephen Henry awarded a Doctor of Science
The University of Auckland awards Stephen Henry a DSc for his thesis on Kode Technology, now free to download.
Downloads → 21 Feb 2023Kode Technology Illustrated Technical Manual published
The illustrated technical manual brings together technical information on Kode Technology and FSL constructs for scientists.
Downloads →Work with us: partner with kode
Licensing, research collaboration and custom FSL constructs.
